Focused on neurodegenerative diseases that affect millions of patients worldwide
Novel Treatments for Neurodegenerative Conditions
NeuroBo Pharmaceuticals is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease.
Our first product candidate, NB-01, is targeting neuropathic pain with a first indication in PDN. Phase 3 studies are planned and powered for efficacy and safety.
PDN affects 8.4M people worldwide representing global drug sales of $3.05B (2018, GlobalData)
Diabetes and cancer are amongst the leading causes of neuropathic pain
Symptoms range from dull and tingling to debilitating pain; limiting mobility, negatively impacting sleep, and hindering glycemic control (Ormseth et al. 2011)
Current treatments show 30% reduction of pain in 40% of patients
Only three approved therapies for PDN with high rates of adverse events
When these fail, even in combination, physicians often turn to off-label use of opioids
NB-02, our lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s Disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth).
Alzheimer’s disease affects 10.6M people globally (2016, Global Data)
Approved treatments focus on symptomatic management and largely on acetyl cholinesterase (AChE) inhibition
650+ drug trials underway targeting Tau inhibition, amyloid plaque inhibition, and combinations with AChE inhibition
>20 diseases that result from tau protein aggregation in the brain; progressive supranuclear palsy (PSP) is a key focus
No current approved therapies for patients with tauopathies